{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0"}]}],"title":"6 months overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"}]}],"title":"12 months overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0"}]}],"title":"24 months overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0"}]}],"title":"36 months overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0"}]}],"title":"48 months overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5"}]}],"title":"60 months overall survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival","groups":[{"description":"Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.\n\nAntineoplaston therapy (Atengenal + Astugenal): Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).","id":"OG000","title":"Antineoplaston Therapy"}],"paramType":"NUMBER","populationDescription":"All study subjects receiving any Antineoplaston therapy","reportingStatus":"POSTED","timeFrame":"6 months, 12 months, 24 months, 36 months, 48 months, 60 months","title":"Percentage of Participants Who Survived","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}